Nemedis Inc. positions itself as an AI solutions company for the healthcare industry, with a focus on radiology-assisted diagnosis and medical software integration. Its core product, PulmoScan, is mainly used to detect lung abnormalities and respiratory diseases from standard radiological images, especially X-Rays, including COVID-19, bacterial pneumonia, viral pneumonia, and others.
According to the official website, Nemedis uses proprietary, ground-up, customizable deep-learning algorithms based on artificial neural networks, and offers both cloud-based and integrated solutions. Typical use cases include healthcare providers using PulmoScan to speed up patient diagnosis, radiology departments connecting AI capabilities to existing imaging hardware and software, and the development of customized medical software UIs. The website states that PulmoScan has diagnosed 600+ X-ray images and is used by 8 medical institutions worldwide, with a claimed accuracy of 98%+.
The scraped text does not disclose a free trial, subscription pricing, usage-based billing, enterprise procurement model, or payment methods. On the integration side, Nemedis explicitly offers custom integration for existing Radiology hardware and software, and can develop unique medical UI applications. However, there is no detailed information about standard APIs, SDKs, or compatibility with DICOM/PACS/RIS.
Its strengths are a clear focus on the vertical field of medical imaging, well-defined application scenarios, and an emphasis on cloud deployment, custom algorithms, and system integration capabilities. For healthcare institutions, a solution like this could potentially improve screening efficiency if it can be connected smoothly with existing imaging workflows. The main drawback is the limited amount of public information: there is no explanation of the clinical validation design, sample sources, sensitivity/specificity, regulatory approvals, data privacy and security compliance, or Chinese-language support. The claimed 98% accuracy should be interpreted cautiously in the context of the test set and real-world performance.
Nemedis is better suited to hospitals or diagnostic centers that need an AI pilot for imaging departments and are willing to discuss custom integration. It is not ideal as an out-of-the-box tool for individual doctors. Access from China is unknown. Given that deploying medical AI in China involves networking, cross-border data transfer, compliance approvals, and local payment considerations, Chinese institutions should generally also evaluate domestic alternatives such as ζ¨ζ³ε»η and ζ°ε€η§ζ, or comparable international providers such as Lunit, Aidoc, and Qure.ai.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on nemedis.com official site.
nemedis.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach nemedis.com directly.